GENOPIA Biomedical LLC (GENOPIA), a biotechnology firm headquartered in Saarbücken, Germany and Ciphergen Biosystems, Inc. (Nasdaq: CIPH) in Fremont, CA, will collaborate on the discovery and the development of new drug targets and candidates for CNS diseases. GENOPIA Biomedical focuses on the development of novel drug candidates and uses advanced proteomics as its main drug discovery and high-throughput screening tool, while Ciphergen Biosystems is a world leader in the development of proteomics technology, most notably its SELDI (Surface-Enhanced Laser Desorption/Ionization) ProteinChip® technology. The close collaboration between GENOPIA and Ciphergen reflects the growing importance of proteomics in modern drug discovery. Plans include the joint development of highly customized ProteinChip® surfaces to meet GENOPIA ’s needs for its proprietary drug targets.
Drs. Bernhard Schu (CEO) and Helge Völkel (CSO) of GENOPIA , commented on the collaboration between the two companies: "Stroke is one of the most common neurological conditions, and represents one of the largest pharmaceutical markets in the 21st century. Scientists at GENOPIA have identified proteins that play key roles in the cellular response to hypoxia and hypoxia-reperfusion injury, key components of stroke. In a mouse model of stroke, we were able to demonstrate the importance of these target proteins. The use of specially adapted, state-of-the-art Ciphergen ProteinChip® technology will greatly accelerate our drug discovery process, and also allow us to shorten the time to further characterize our already identified drug candidates."
Drs. Bernhard Schu and Helge Voelkel continued "The objective is to accelerate protein biology research, with the same ease and success in which genomic and molecular biology research is done today. We envision new products that combine the expertise of both companies to create rapid ‘gene to protein’ transcription, translation, and protein purification capabilities at various scales, tagged or tag-free, as well as advanced ‘on-chip’ molecular-interaction and cellular assay platforms that further enable functional genomics."
What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering